Shield Therapeutics plc
STX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £24 | £48 | £16 | £91 |
| - Cash | £6 | £14 | £3 | £12 |
| + Debt | £21 | £20 | £6 | £0 |
| Enterprise Value | £40 | £55 | £20 | £79 |
| Revenue | £25 | £13 | £5 | £2 |
| % Growth | 92.5% | 138% | 262% | – |
| Gross Profit | £11 | £4 | £2 | £1 |
| % Margin | 42% | 30.8% | 36.3% | 35.5% |
| EBITDA | -£17 | -£30 | -£46 | -£18 |
| % Margin | -65.8% | -231.5% | -837.7% | -1,164.7% |
| Net Income | -£21 | -£33 | -£40 | -£19 |
| % Margin | -84.5% | -254.4% | -735.5% | -1,272.9% |
| EPS Diluted | -0.024 | -0.037 | -0.17 | -0.095 |
| % Growth | 36.7% | 78.2% | -79.7% | – |
| Operating Cash Flow | -£7 | -£37 | -£18 | -£17 |
| Capital Expenditures | -£0 | -£3 | -£2 | -£2 |
| Free Cash Flow | -£7 | -£40 | -£20 | -£19 |